Background Since December, 2019, Wuhan, China, has experienced an outbreak of
coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome …

Background The long-term health consequences of COVID-19 remain largely unclear. The
aim of this study was to describe the long-term health consequences of patients with COVID-…

Background A recent cluster of pneumonia cases in Wuhan, China, was caused by a novel
betacoronavirus, the 2019 novel coronavirus (2019-nCoV). We report the epidemiological, …

Background No therapeutics have yet been proven effective for the treatment of severe
illness caused by SARS-CoV-2. Methods We conducted a randomized, controlled, open-label …

Background No specific antiviral drug has been proven effective for treatment of patients
with severe coronavirus disease 2019 (COVID-19). Remdesivir (GS-5734), a nucleoside …

Background The full range of long-term health consequences of COVID-19 in patients who
are discharged from hospital is largely unclear. The aim of our study was to comprehensively …

Background With the ongoing COVID-19 pandemic, growing evidence shows that a
considerable proportion of people who have recovered from COVID-19 have long-term effects on …

Background The memory immune response is crucial for preventing reinfection or reducing
disease severity. However, the robustness and functionality of the humoral and T-cell …

Background The long-term health consequences of COVID-19 remain largely unclear. The
aim of this study was to describe the long-term health consequences of patients with COVID-…

Background Simnotrelvir is an oral 3-chymotrypsin–like protease inhibitor that has been
found to have in vitro activity against severe acute respiratory syndrome coronavirus 2 (SARS-…